Chemotherapy-induced nail discoloration
How to cite this article: Yumnam D, Moirangthem A. Chemotherapy-induced nail discoloration. CosmoDerma 2022;2:100.
An 8-year-old boy, diagnosed case of acute myeloid leukemia, was treated with Berlin-Frankfurt-Munich 2009 regimen which includes cytarabine, etoposide, and idarubicin. After 4 weeks of commencing the regime, the patient presented to the dermatology clinic for hyperpigmented bands on the nails (chromonychia). Nail examination showed a transverse, 2–4 mm broad, brownish band (black arrow in [Figures 1 and 2]; melanonychia) across the entire nail breadth, distal, and parallel to the lunulae which are non-blanchable and non-palpable with smooth overlying nail surface on the nail plates of all fingers and toes [Figures 1 and 2]. These transverse lines moved distally with nail growth and finally disappeared after 6 months of stoppage of chemotherapy. Melanonychia is the brownish-black discoloration of nails due to the deposition of melanin. It can be diffuse, longitudinal, or transverse. Chemotherapeutic agents including etoposide, cytarabine, and idarubicin have all been recognized to cause melanonychia.[1,2] Other chemotherapeutic agents reported are bleomycin, cyclophosphamide, daunorubicin, dacarbazine, 5-fluorouracil, hydroxyurea, methotrexate, and vincristine. Chemotherapy can also cause other nail changes such as Mees line, Muehrcke’s line, Beau’s line, onycholysis, and paronychia. Drug-induced nail abnormalities result from toxicity to the matrix, nail bed, or nail bed blood vessels. Nail changes after chemotherapy are one of the distressing side effects, early recognition is necessary to reduce anxiety among patients and avoid any dispensable workup.
Declaration of patient consent
The authors certify that they have obtained all appropriate patient consent.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
- Idarubicin-induced pigmentary changes of the nails. Cutis. 1997;59:203-4.
- [Google Scholar]